Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03666351
Other study ID # HM_AMO_401
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 18, 2018
Est. completion date July 25, 2022

Study information

Verified date September 2022
Source Hanmi Pharmaceutical Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To compare changes in Left Ventricular Mass (LVM) depending on each blood pressure regulation between the intensive care group and the usual care group for patients with hypertension accompanied by aortic valve disease and evaluate an influence of blood pressure regulation on improvement of left ventricular hypertrophy and its safety


Description:

1.Primary objectives - To evaluate changes from baseline in LVM at V5 (24M) 2.Secondary objectives 1. To evaluate changes from baseline in LV global longitudinal strain at V5 (24M) 2. To evaluate changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at V5 (24M) 3. To evaluate changes from baseline in LV volumes, a stroke volume index and LV ejection fraction at V5 (24M) 4. To evaluate a rate of disease progression - In case of Aortic stenosis (AS), to evaluate changes from baseline in Aortic Valve Area (AVA), Vmax, Mean Pressure Gradient (PG) and Valvulo-arterial impedance (Zva) at V5 (24M) - In case of Aortic regurgitation (AR), to evaluate changes from baseline in Vena contracta at V5 (24M) 5. To evaluate changes from baseline in blood pressure at V2(6M), V3(12M), V4(18M) and V5(24M) 6. To evaluate a cumulative incidence rate for each visit time point - Death, Cardiovascular(CV) death, Heart Failure(HF), Myocardial Infarction(MI), Hospitalization, Aortic Valve Replacement(AVR) 7. To evaluate outcomes of adverse events, physical examination, vital signs (pulse) and laboratory tests (hematological examination, blood biochemical examination, urine test and pregnancy test)


Recruitment information / eligibility

Status Completed
Enrollment 128
Est. completion date July 25, 2022
Est. primary completion date July 25, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years to 80 Years
Eligibility Inclusion Criteria: 1. Male or female aged = 19 years and < 80 years 2. Diagnosis of mild-moderate AS or mild-moderate AR 3. Applicable to 2.0~3.9 m/s of aortic jet velocity for mild-moderate AS or to 0.2~0.6 cm of Vena contracta for mild-moderate AR 4. Diagnosis of hypertension (SBP > 130 mmHg if being treated or SBP > 140 mmHg if being untreated) 5. For females of childbearing potential; negative pregnancy test results during the screening period and prior to administration of the investigational product, and agreement on use of medically allowable contraceptive measures (condom, oral contraceptive pills, injectable or implantable contraceptives, intrauterine devices, birth control patches, etc.) during the study period 6. Voluntary written consent to taking part in the clinical study and willingness to comply with requirements of the study Exclusion Criteria: 1. History of a cardiac valve replacement surgery (replacement surgery of mitral valve, aortic valve or tricuspid valve) 2. Accompanied by severe mitral regurgitation 3. Admitted to needing a surgery by the current treatment guidelines 4. Accompanied by symptoms such as angina pectoris, exertional dyspnea, syncope, etc. 5. < 50% of left ventricular ejection fraction 6. History of hypersensitivity reaction to active ingredients of the investigational product (Amlodipine, Losartan and Chlorthalidone), dihydropyridine derivatives, thiazide drugs and other sulfonamide derivatives or their compositions 7. Pregnant or breastfeeding 8. Symptomatic orthostatic hypotension 9. Severe liver failure or renal failure (< 30 mL/min of creatinine clearance) 10. Hereditary angioedema or history of angioedema at treatment with ACE inhibitors or angiotensin II receptor blockers 11. Primary hyperaldosteronism 12. Genetic problems such as galactose intolerance, Lapp Lapp lactase deficiency or glucose-galactose malabsorption 13. Anuria 14. Refractory hypokalemia 15. Hyponatremia or hypercalcemia 16. Symptomatic hyperuricemia (history of gout or uric acid lithiasis) 17. Untreated Addison's disease 18. Appropriately uncontrolled diabetes 19. Congenital or incurable hypertension 20. Diagnosis of severe cerebrovascular disorders (stroke, cerebral infarction, cerebral hemorrhage, etc.) within six months prior to the date of ICF obtainment 21. Wasting disease, autoimmune disease or connective tissue disease 22. Diagnosis of malignant tumor within five years prior to the date of ICF obtainment 23. Administration of another investigational product within four weeks prior to the date of ICF obtainment 24. For a patient who is taking anticoagulants and thrombolytic agents; considered difficult to keep a stable dosage/regimen by the investigator. 25. Considered unsuitable to be a subject by the investigator

Study Design


Intervention

Drug:
Amlodipine 5mg
Amlodipine 5 mg
Losartan
Losartan Potassium 50 mg
Losartan and Amlodipine
Amlodipine 5 mg/Losartan Potassium 50 mg, Amlodipine 5 mg/Losartan Potassium 100 mg
Amlodipine/Losartan/Chlorthalidone
Amlodipine 5 mg/Losartan Potassium 100 mg/Chlorthalidone 12.5 mg
current treatment
treatment is done by maintaining the current treatment

Locations

Country Name City State
Korea, Republic of 10 Institutions Including Asan Medical Center Seoul

Sponsors (1)

Lead Sponsor Collaborator
Hanmi Pharmaceutical Company Limited

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Other Occurrence and frequency of adverse events Occurrence and frequency of adverse events 6 months, 12 months, 18 months, 24 months
Primary To evaluate changes from baseline in Left Ventricular Mass at 24M To evaluate changes from baseline in Left Ventricular Mass at 24M 24 months
Secondary Changes from baseline in Left Ventricular global longitudinal strain at 24M Changes from baseline in Left Ventricular global longitudinal strain at 24M 24 months
Secondary Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M Changes from baseline in E/E' (E: early diastolic LV inflow velocity, E': early diastolic mitral annulus velocity) at 24M 24 months
Secondary Changes from baseline in Left Ventricular volumes at 24M Changes from baseline in Left Ventricular volumes at 24M 24 months
Secondary Rate of disease progression In case of Aortic Stenosis, to evaluate changes from baseline in Aortic Valve Area, tricuspid regurgitation velocity, Mean Pressure Gradient and Valvulo-arterial impedance at 24M
In case of Aortic Regurgitation, to evaluate changes from baseline in Vena contracta at 24M
24 months
Secondary To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M To evaluate changes from baseline in systolic blood pressure at 6M, 12M, 18M, 24M 6 months, 12 months, 18 months, 24 months
Secondary Cumulative incidence rate for each visit time point Cumulative incidence rate for each visit time point
- Death, Cardiovascular death, Heart Failure, Myocardial Infarction, Hospitalization, Aortic Valve Replacement
6 months, 12 months, 18 months, 24 months
Secondary Changes from baseline in stroke volume index at 24M Changes from baseline in stroke volume index at 24M 24 months
Secondary Changes from baseline in Left Ventricular ejection fraction at 24M Changes from baseline in Left Ventricular ejection fraction at 24M 24 months
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A